Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 13-Sep-24 5:26 PM View:  | Saharek John P. CEO of ImprimisRx | Transdel Pharmaceuticals, I... (HROW) | 11-Sep-24 | Payment of Exercise | 45,140 | $41.37 | $1,867,440.00 | (13%) 344.8K to 299.66K | |
| 13-Sep-24 5:26 PM View: | Saharek John P. CEO of ImprimisRx | Transdel Pharmaceuticals, I... (HROW) | 11-Sep-24 | Option Exercise | 90,000 | $7.37 | $663,300.00 | 35% 254.8K to 344.8K | |
| 25-Apr-24 5:19 PM View: | Opaleye Management Inc. 10% Owner | Transdel Pharmaceuticals, I... (HROW) | 25-Apr-24 | Purchase | 20,000 | $9.97 | $199,400.00 | < 1% 3.79M to 3.81M | |
| 24-Apr-24 4:40 PM View: | Opaleye Management Inc. 10% Owner | Transdel Pharmaceuticals, I... (HROW) | 24-Apr-24 | Purchase | 8,285 | $10.15 | $84,092.80 | < 1% 3.79M to 3.79M | |
| 24-Apr-24 4:40 PM View: | Opaleye Management Inc. 10% Owner | Transdel Pharmaceuticals, I... (HROW) | 23-Apr-24 | Purchase | 11,715 | $10.29 | $120,547.00 | < 1% 3.78M to 3.79M | |
| 19-Apr-24 6:24 PM View: | Opaleye Management Inc. 10% Owner | Transdel Pharmaceuticals, I... (HROW) | 19-Apr-24 | Purchase | 29,400 | $10.56 | $310,390.00 | < 1% 3.75M to 3.77M | |
| 28-Mar-24 6:07 PM View: | Opaleye Management Inc. 10% Owner | Transdel Pharmaceuticals, I... (HROW) | 28-Mar-24 | Purchase | 50,000 | $12.82 | $641,000.00 | 1% 3.7M to 3.75M | |
| 25-Mar-24 7:00 AM View: | Baum Mark L Chief Executive Officer Director | Transdel Pharmaceuticals, I... (HROW) | 22-Mar-24 | Purchase | 9,000 | $11.59 | $104,310.00 | < 1% 2.13M to 2.14M | |
| 22-Mar-24 11:52 AM View: | Opaleye Management Inc. 10% Owner | Transdel Pharmaceuticals, I... (HROW) | 20-Mar-24 | Purchase | 50,600 | $9.65 | $488,290.00 | 1% 3.65M to 3.7M | |
| 06-Mar-24 6:06 AM View: | Saharek John P. CEO of ImprimisRx | Transdel Pharmaceuticals, I... (HROW) | 01-Mar-24 | Option Exercise | 5,000 | $8.75 | $43,750.00 | 2% 249.8K to 254.8K | (7%) |
| 21-Feb-24 7:29 PM View: | Boll Andrew Chief Financial Officer | Transdel Pharmaceuticals, I... (HROW) | 20-Feb-24 | Option Exercise | 45,000 | $10.67 | $480,150.00 | 8% 541.57K to 586.57K | |
| 21-Feb-24 7:29 PM View: | Baum Mark L Chief Executive Officer Director | Transdel Pharmaceuticals, I... (HROW) | 20-Feb-24 | Option Exercise | 59,836 | $10.67 | $638,450.00 | (3%) 2.19M to 2.13M | |
| 21-Feb-24 7:30 PM View: | Saharek John P. CEO of ImprimisRx | Transdel Pharmaceuticals, I... (HROW) | 20-Feb-24 | Option Exercise | 30,000 | $10.67 | $320,100.00 | 13% 232.42K to 262.42K | |
| 21-Feb-24 7:29 PM View: | Boll Andrew Chief Financial Officer | Transdel Pharmaceuticals, I... (HROW) | 20-Feb-24 | Option Exercise | 18,480 | $10.67 | $197,182.00 | (3%) 586.57K to 568.09K | |
| 21-Feb-24 7:30 PM View: | Saharek John P. CEO of ImprimisRx | Transdel Pharmaceuticals, I... (HROW) | 20-Feb-24 | Option Exercise | 12,616 | $10.67 | $134,613.00 | (5%) 262.42K to 249.8K | |
| 21-Feb-24 7:29 PM View: | Baum Mark L Chief Executive Officer Director | Transdel Pharmaceuticals, I... (HROW) | 20-Feb-24 | Option Exercise | 150,000 | $10.67 | $1,600,500.00 | 7% 2.04M to 2.19M | |
| 08-Feb-24 7:30 AM View: | Baum Mark L Chief Executive Officer Director | Transdel Pharmaceuticals, I... (HROW) | 07-Feb-24 | Option Exercise | 15,400 | $7.71 | $118,734.00 | < 1% 2.02M to 2.04M | 6% |
| 08-Feb-24 7:30 AM View: | Boll Andrew Chief Financial Officer | Transdel Pharmaceuticals, I... (HROW) | 07-Feb-24 | Option Exercise | 7,400 | $7.71 | $57,054.00 | 1% 534.17K to 541.57K | 6% |
| 16-Nov-23 4:45 PM View: | Baum Mark L Chief Executive Officer Director | Transdel Pharmaceuticals, I... (HROW) | 16-Nov-23 | Market Purchase | 7,500 | $8.11 | $60,825.00 | < 1% 2.02M to 2.02M | < 1% |
| 16-Nov-23 4:05 PM View: | Opaleye Management Inc. 10% Owner | Transdel Pharmaceuticals, I... (HROW) | 15-Nov-23 | Market Purchase | 25,000 | $8.03 | $200,735.00 | < 1% 3.62M to 3.65M | 2% |
| 14-Nov-23 7:02 PM View: | Saharek John P. Chief Commercial Officer | Transdel Pharmaceuticals, I... (HROW) | 10-Nov-23 | Payment of Exercise | 9,778 | $12.83 | $125,452.00 | (4%) 242.2K to 232.42K | |
| 14-Nov-23 7:02 PM View: | Saharek John P. Chief Commercial Officer | Transdel Pharmaceuticals, I... (HROW) | 10-Nov-23 | Option Exercise | 20,000 | -- | -- | 9% 222.2K to 242.2K | |
| 20-Sep-23 6:39 PM View: | Opaleye Management Inc. 10% Owner | Transdel Pharmaceuticals, I... (HROW) | 20-Sep-23 | Purchase | 5,983 | $14.49 | $86,710.40 | < 1% 3.61M to 3.62M | |
| 20-Sep-23 6:39 PM View: | Opaleye Management Inc. 10% Owner | Transdel Pharmaceuticals, I... (HROW) | 19-Sep-23 | Purchase | 14,017 | $14.65 | $205,366.00 | < 1% 3.6M to 3.61M | |
| 15-Aug-23 7:30 AM View: | Makary Martin A. Director | Transdel Pharmaceuticals, I... (HROW) | 14-Aug-23 | Purchase | 20,000 | $16.92 | $338,400.00 | 80% 25.0K to 45.0K | |
| 15-Aug-23 7:30 AM View: | Baum Mark L Chief Executive Officer Director | Transdel Pharmaceuticals, I... (HROW) | 14-Aug-23 | Purchase | 5,800 | $17.05 | $98,890.00 | < 1% 2.01M to 2.02M | |
| 20-Jul-23 7:43 PM View: | Boll Andrew Chief Financial Officer | Transdel Pharmaceuticals, I... (HROW) | 18-Jul-23 | Payment of Exercise | 136,350 | $18.23 | $2,485,660.00 | (20%) 670.52K to 534.17K | |
| 20-Jul-23 7:43 PM View: | Boll Andrew Chief Financial Officer | Transdel Pharmaceuticals, I... (HROW) | 18-Jul-23 | Option Exercise | 346,500 | -- | -- | 107% 324.02K to 670.52K | |
| 20-Jul-23 7:48 PM View: | Baum Mark L Chief Executive Officer Director | Transdel Pharmaceuticals, I... (HROW) | 18-Jul-23 | Payment of Exercise | 299,968 | $18.23 | $5,468,420.00 | (13%) 2.31M to 2.01M | |
| 20-Jul-23 7:48 PM View: | Baum Mark L Chief Executive Officer Director | Transdel Pharmaceuticals, I... (HROW) | 18-Jul-23 | Option Exercise | 762,300 | -- | -- | 49% 1.55M to 2.31M | |
| 20-Jul-23 7:46 PM View: | Saharek John P. Chief Commercial Officer | Transdel Pharmaceuticals, I... (HROW) | 18-Jul-23 | Option Exercise | 277,200 | -- | -- | 513% 54.08K to 331.28K | |
| 20-Jul-23 7:46 PM View: | Saharek John P. Chief Commercial Officer | Transdel Pharmaceuticals, I... (HROW) | 18-Jul-23 | Payment of Exercise | 109,080 | $18.23 | $1,988,530.00 | (33%) 331.28K to 222.2K | |
| 04-Apr-23 7:54 PM View: | Baum Mark L Chief Executive Officer Director | Transdel Pharmaceuticals, I... (HROW) | 03-Apr-23 | Payment of Exercise | 117,633 | $20.97 | $2,466,760.00 | (7%) 1.66M to 1.55M | |
| 04-Apr-23 7:54 PM View: | Baum Mark L Chief Executive Officer Director | Transdel Pharmaceuticals, I... (HROW) | 03-Apr-23 | Option Exercise | 180,000 | $8.99 | $1,618,200.00 | 12% 1.48M to 1.66M | (9%) |
| 04-Apr-23 7:50 PM View: | Boll Andrew Chief Financial Officer | Transdel Pharmaceuticals, I... (HROW) | 31-Mar-23 | Payment of Exercise | 34,442 | $21.16 | $728,793.00 | (10%) 358.46K to 324.02K | |
| 04-Apr-23 7:50 PM View: | Boll Andrew Chief Financial Officer | Transdel Pharmaceuticals, I... (HROW) | 31-Mar-23 | Option Exercise | 90,000 | $6.00 | $540,000.00 | 34% 268.46K to 358.46K | |
| 03-Jan-23 9:53 PM View: | Boll Andrew Chief Financial Officer | Transdel Pharmaceuticals, I... (HROW) | 02-Jan-23 | Payment of Exercise | 9,602 | $14.76 | $141,726.00 | (3%) 278.06K to 268.46K | |
| 03-Jan-23 9:53 PM View: | Boll Andrew Chief Financial Officer | Transdel Pharmaceuticals, I... (HROW) | 02-Jan-23 | Option Exercise | 23,000 | -- | -- | 9% 255.06K to 278.06K | |
| 03-Jan-23 9:52 PM View: | Baum Mark L Chief Executive Officer Director | Transdel Pharmaceuticals, I... (HROW) | 02-Jan-23 | Payment of Exercise | 35,179 | $14.76 | $519,242.00 | (2%) 1.52M to 1.48M | |
| 03-Jan-23 9:52 PM View: | Baum Mark L Chief Executive Officer Director | Transdel Pharmaceuticals, I... (HROW) | 02-Jan-23 | Option Exercise | 88,000 | -- | -- | 6% 1.43M to 1.52M | |
| 23-Dec-22 7:00 AM View: | van Horn R. Lawrence Director | Transdel Pharmaceuticals, I... (HROW) | 22-Dec-22 | Purchase | 1,860 | $13.42 | $24,961.20 | 100% 0 to 1.86K | |
| 23-Dec-22 7:02 AM View: | Boll Andrew Chief Financial Officer | Transdel Pharmaceuticals, I... (HROW) | 22-Dec-22 | Purchase | 2,500 | $13.54 | $33,850.00 | < 1% 252.56K to 255.06K | |
| 23-Dec-22 7:03 AM View: | Baum Mark L Chief Executive Officer Director | Transdel Pharmaceuticals, I... (HROW) | 22-Dec-22 | Purchase | 25,000 | $13.39 | $334,750.00 | 2% 1.41M to 1.43M | |
| 23-Dec-22 7:01 AM View: | Makary Martin A. Director | Transdel Pharmaceuticals, I... (HROW) | 21-Dec-22 | Purchase | 25,000 | $13.37 | $334,250.00 | 100% 0 to 25.0K | |
| 14-Dec-22 4:05 PM View: | Opaleye Management Inc. 10% Owner | Transdel Pharmaceuticals, I... (HROW) | 14-Dec-22 | Purchase | 431,183 | $10.52 | $4,536,050.00 | 13% 3.34M to 3.77M | |
| 03-Oct-22 6:02 PM View: | Lindstrom Richard L Md Director | Transdel Pharmaceuticals, I... (HROW) | 30-Sep-22 | Private Sale (Planned) | 40,000 | $12.62 | $504,800.00 | (24%) 166.1K to 126.1K | |
| 30-Sep-22 6:15 AM View: | Opaleye Management Inc. 10% Owner | Transdel Pharmaceuticals, I... (HROW) | 28-Sep-22 | Purchase | 11,085 | $9.77 | $108,354.00 | < 1% 3.33M to 3.34M | |
| 13-Apr-22 6:33 PM View: | Opaleye Management Inc. 10% Owner | Transdel Pharmaceuticals, I... (HROW) | 13-Apr-22 | Purchase | 12,832 | $6.76 | $86,785.40 | < 1% 3.32M to 3.33M | |
| 13-Apr-22 6:33 PM View: | Opaleye Management Inc. 10% Owner | Transdel Pharmaceuticals, I... (HROW) | 12-Apr-22 | Private Purchase | 28,557 | $6.75 | $192,717.00 | < 1% 3.29M to 3.32M | |
| 23-Feb-22 6:00 PM View: | Boll Andrew Chief Financial Officer | Transdel Pharmaceuticals, I... (HROW) | 19-Feb-22 | Option Exercise | 50,000 | -- | -- | 22% 223.17K to 273.17K |
